OncoMatch/Clinical Trials/NCT07127874
A Study of PHN-012 in Patients With Advanced Solid Tumors
Is NCT07127874 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PHN-012 for colon cancer.
Treatment: PHN-012 — This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy
Cannot have received: antibody-drug conjugate with topoisomerase-1 inhibiting payload
Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- PHN-012-001 Site · Los Angeles, California
- PHN-012-001 Site · Washington D.C., District of Columbia
- PHN-012-001 Site · Boston, Massachusetts
- PHN-012-001 Site · St Louis, Missouri
- PHN-012-001 Site · Durham, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify